BCL9L and cholangiocarcinoma: In our study, we found that silencing LINC00665 suppressed BCL9L expression, and subsequently decreased nucleus translocation of β-Catenin and Wnt signaling activation, therefore impaired gemcitabine-induced EMT and stemness of resistant CCA cells.